Vida Ventures
ActiveFiled to raiseBoston, MABiotechnology, Healthcare, PharmaceuticalsLast fund filed 2026
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Vida Ventures IVFiled to raise in 2026, with no closing reported yet. | 2026 | $500M | $0 | 0 |
| Vida Ventures IIIFiled to raise in 2021, with no closing reported yet. | 2021 | $750M | $0 | 0 |
| VIDA VENTURES II-A | July 2019 | $600M | $16M | 10 |
| Vida Ventures II | July 2019 | $600M | $537M | 109 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
10 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Matthew CohenNot on the current fund | Selective | Biotech & pharma, Digital health, Climate & energy | 10 |
Classified sectors of Vida Ventures’s own portfolio companies, based on 54 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| MPM BioVentures | 4 | Aktis Oncology, HotKnot Therapeutics, Orna Therapeutics Holdings, RECODE THERAPEUTICS |
| Orbimed Asia Partners | 4 | Alterome Therapeutics, Capstan Therapeutics, RECODE THERAPEUTICS, Roka BioScience |
| Orbimed Genesis | 4 | Alterome Therapeutics, Capstan Therapeutics, RECODE THERAPEUTICS, Roka BioScience |
| November 2017 |
| $255M |
| $255M |
| 58 |
| 3 |
| Fred Cohen | Selective | Biotech & pharma, Digital health, Gaming & entertainment | 13 | 2 |
| Arie Belldegrun | Slowing | Biotech & pharma, Food & agriculture, Manufacturing & industrials | 6 | 1 |
| Rajul JainNot on the current fund | Slowing | Biotech & pharma | 5 | 1 |
| Stefan Vitorovic | Slowing | Biotech & pharma | 5 | 1 |
| Arjun Goyal | Quiet | Biotech & pharma | 6 | 0 |
| Brian GoodmanNot on the current fund | Quiet | Biotech & pharma | 3 | 0 |
| Helen Kim | Quiet | Biotech & pharma | 8 | 0 |
| Jean-Philippe Kouakou-ZebouahNot on the current fund | Quiet | None listed | 0 | 0 |
| Leonard Potter | Quiet | Digital health, Biotech & pharma, E-commerce & marketplaces | 6 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Vida Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 4 |
| ByHeart, MeridianMade, Tectonic Therapeutic, Volastra Therapeutics |
| Abingworth Bioventures | 2 | Protego Biopharma, Scorpion Therapeutics |
| ARCH Venture Partners | 2 | Ollin Biosciences, SonoThera |
| Atlas Venture | 2 | Scorpion Therapeutics, Vigil Neuroscience |
| Caduceus Capital | 2 | Alterome Therapeutics, Roka BioScience |
| Nextech Viii Carry Scsp | 2 | A2 Biotherapeutics, IconOVir Bio |
| Rise | 2 | Allogene Therapeutics, Kite Pharma |
| TPG Healthcare Partners | 2 | Allogene Therapeutics, Kite Pharma |
| TPG Personnel | 2 | Allogene Therapeutics, Kite Pharma |
| Versant Affiliates | 2 | Cell Design Labs, VERACYTE |
| Versant Venture Capital | 2 | Cell Design Labs, VERACYTE |
| Westlake Biopartners | 2 | Auxogyn, Cell Design Labs |
A shared board seat: a company where filings name a Vida Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.